DESTINY-Lung02 is a phase II study that evaluated the efficacy and safety of T-DXd 5.4 mg/kg and 6.4 mg/kg in 102 and 50 patients with HER2 MUT NSCLC, respectively, obtaining very interesting results: ORRs of 50% and 56%, mPFS of 10.0 months and 12.9 months, and mOS of 19.0 months and 17.3 months with 5.4 mg/kg and 6.4 mg/kg, respectively. The gene discussed is ERBB2; the disease is non-small cell lung carcinoma.